Ocular Therapeutix, Inc. provided revenue guidance for the full year 2022. For the year, the company expected total net product revenue to be in the range of $55 million to $60 million, representing growth of between 26% to 38% over 2021. The growth is anticipated to be primarily driven by sales of DEXTENZA for the treatment of post-surgical inflammation and pain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6 USD | -1.64% | -4.61% | +34.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.53% | 93Cr | |
+37.74% | 72TCr | |
+34.77% | 59TCr | |
-2.07% | 37TCr | |
+20.25% | 33TCr | |
+2.99% | 28TCr | |
+16.49% | 24TCr | |
+9.63% | 21TCr | |
-4.74% | 21TCr | |
+7.43% | 17TCr |
- Stock Market
- Equities
- OCUL Stock
- News Ocular Therapeutix, Inc.
- Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022